Li Wei, Liu Min, Feng Yuan, Xu Yun-Fei, Che Jian-Ping, Wang Guang-Chun, Zheng Jun-Hua, Gao Heng-Jun
Department of Urology, Shanghai Tenth People's Hospital, Tongji University, Shanghai, 200072, China.
Int J Clin Exp Pathol. 2013 May 15;6(6):1086-94. Print 2013.
Argonaute subfamily proteins are involved in human organ growth and development. Recent studies found its association with human breast cancer, however, its expression profile and its prognostic value in clear cell renal cancer (ccRCC) have not been investigated.
Expression of the Argonaute proteins were assessed by immunohistochemistry (IHC) in tissue microarrays (TMA), containing paired tumor tissue and adjacent non-cancer tissue from 176 patients who had undergone surgery in hospital for histologically proven ccRCC. Prognostic value and correlation with other clinico-pathologic factors were evaluated in two classifications.
Data showed a significant higher expression of Argonaute 1 and Argonaute 2 present in neoplastic tissues compared with that in adjacent tissue; A significant correlation existed between the higher expression of Argonaute 1 protein with the T stage, lymph node metastasis and clinical TNM (cTNM); Survival analysis by Kaplan-Meier survival curve and log-rank test demonstrated that elevated Argonaute 1 and Argonaute 2 expression in cancer tissue predicted poorer overall survival (OS) compared with group in lower expression (36.3% VS 67.1%; 37.3% VS 53.9%; respectively). Notably, multivariate analyses by Cox's proportional hazard model revealed that expression of Argonaute 2 was an independent prognostic factor in renal cancer.
In summary, our present study clarify that the aberrant expression of Argonaute in human RCC is possibly involved with tumorigenesis and development, and the Argonaute protein could act as a potential biomarker for prognosis assessment of renal cancer. Related mechanism is worthy of further investigation.
AGO蛋白家族成员参与人体器官的生长发育。近期研究发现其与人类乳腺癌有关,然而,其在肾透明细胞癌(ccRCC)中的表达谱及其预后价值尚未得到研究。
采用免疫组化(IHC)方法在组织芯片(TMA)中评估AGO蛋白的表达,该芯片包含176例经手术治疗且病理确诊为ccRCC患者的配对肿瘤组织和相邻非癌组织。在两种分类中评估其预后价值以及与其他临床病理因素的相关性。
数据显示,与相邻组织相比,肿瘤组织中AGO1和AGO2的表达显著更高;AGO1蛋白的高表达与T分期、淋巴结转移和临床TNM(cTNM)之间存在显著相关性;通过Kaplan-Meier生存曲线和对数秩检验进行的生存分析表明,与低表达组相比,癌组织中AGO1和AGO2表达升高预示总体生存期(OS)较差(分别为36.3%对67.1%;37.3%对53.9%)。值得注意的是,Cox比例风险模型的多因素分析显示,AGO2的表达是肾癌的独立预后因素。
总之,我们目前的研究表明,AGO在人类RCC中的异常表达可能与肿瘤发生和发展有关,AGO蛋白可作为评估肾癌预后的潜在生物标志物。相关机制值得进一步研究。